In conclusion, at ≥ 5-year follow-up, first-line nivolumab plus ipilimumab provided long-term efficacy benefits versus chemotherapy in Japanese patients with metastatic NSCLC, regardless of tumor PD-L1 expression. The gene discussed is CD274; the disease is neoplasm.